<unk> , sold under the brand names Xcopri (US) and Ontozry (EU), is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults. It is taken by mouth.<unk>  was approved for medical use in the United States in November 2019 and placed in Schedule V of the Controlled Substances Act in March 2020.<unk>  was approved for medical use in the European Union in March 2021.
Cenobamate
Tetrabamate
Felbamate
Topiramate
Retigabine
Tiagabine
Phenylpiracetam
Lamotrigine